FDA, industry, and patients are talking, but agreement on how to include patient experiences in oncology product prescribing information remains elusive.
According to a JAMA study, only 8.7% of patients with cancer requested medical interventions and only 11.4% of those were deemed inappropriate.
Brain Cancer News
Researcher found an improvement in aromatase inhibitor-associated arthralgia in both omega-3 fatty acids and placebo treatment.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?
- Tumor Infiltrating Lymphocytes Play Prognostic Role in Triple Negative Breast Cancer
- Surgical Margin Status Has No Effect on Prostate Cancer Survival
- CD151—A Striking Marker for Cancer Therapy
- VCD Regimen Preferable as Induction for Newly Diagnosed Multiple Myeloma
- Vitamin D Levels and Risk for Pancreatic Cancer
- Anti-PD-L1 Antibody Demonstrates Antitumor Activity in Triple-Negative Breast Cancer
- New Screening Method May Identify Twice As Many Women with Ovarian Cancer
- Head and Neck Cancers Treatment Regimens
- Role of Genetic Mutations in Metastatic Castrate-Resistant Prostate Cancer Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|